Streptococcus uberis vaccine (inactivated)

This medicine is authorised for use in the European Union.


An overview of Ubac and why it is authorised in the EU

Ubac is a vaccine used in cows and heifers (female cattle that have not yet calved) to reduce clinical mastitis (udder infections with visible signs in milk or the udder) caused by bacteria called Streptococcus uberis, which can reduce milk production. Ubac is also used to reduce the somatic cell count (SCC) in milk, which is a measure of mastitis without visible signs (subclinical mastitis). Ubac contains the active substance called biofilm adhesion component including lipoteichoic acid, which is derived from the sticky film produced by Streptococcus uberis strain 5616.

This EPAR was last updated on 07/12/2021

Authorisation details

Product details
Agency product number
Active substance
Lipoteichoic acid from Biofilm Adhesion Component of Streptococcus uberis, strain 5616
International non-proprietary name (INN) or common name
Streptococcus uberis vaccine (inactivated)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Laboratorios Hipra, S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Avda. La Selva,
135 Amer
17170 Girona

Product information

03/12/2021 Ubac - EMEA/V/C/004595 - IB/0006

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for bovidae

Therapeutic indication

For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in Streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by Streptococcus uberis intramammary infections.

Assessment history

How useful was this page?

Add your rating
1 rating